Merus NV of the Netherlands has secured a research collaboration with Eli Lilly and Co to develop three bispecific antibody therapies for cancer. The deal gives Merus a financial lift while enabling Lilly to enter the bispecific antibody space which is currently occupied by other large pharma companies such as Amgen Inc and Roche.
